CJC-1295 DAC vs No DAC: Research Overview
A research-context comparison of CJC-1295 with and without the Drug Affinity Complex modification — pharmacokinetics, GH secretion patterns, and the implications for pulsatility.
Background
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) based on the first 29 amino acids of the native peptide (GRF 1-29), modified at multiple positions to improve metabolic stability. The base compound — sometimes referred to as Modified GRF(1-29) or Mod GRF(1-29) — exhibits substantially improved resistance to dipeptidyl peptidase IV (DPP-IV) cleavage compared to native GHRH or the earlier Sermorelin (GRF 1-29 unmodified).
The critical pharmacokinetic distinction between CJC-1295 with DAC and without DAC lies in the presence or absence of a maleimidopropionic acid (MPA) linker — the Drug Affinity Complex — that enables covalent binding to endogenous serum albumin post-injection. This modification transforms a short-acting peptide into a long-duration compound, with fundamentally different pharmacodynamic consequences for the GH secretion pattern.
Nomenclature Clarification
The nomenclature in this peptide category is a persistent source of confusion in research literature. For clarity throughout this document: CJC-1295 with DAC refers to the albumin-binding version with prolonged half-life. CJC-1295 without DAC (also called Mod GRF 1-29, Modified GRF 1-29, or tetrasubstituted GRF 1-29) refers to the stabilized but non-albumin-binding version. These are distinct compounds with distinct pharmacological profiles despite shared naming.
The Drug Affinity Complex (DAC)
The DAC technology was developed by ConjuChem Biotechnologies in the early 2000s as a platform for extending peptide half-life via endogenous albumin. When CJC-1295-DAC is injected, the MPA reactive group forms a covalent thioether bond with cysteine-34 on circulating serum albumin. Since albumin has a plasma half-life of approximately 19 days, the peptide-albumin conjugate circulates far longer than the free peptide.
This approach avoids the immunogenicity risks of PEGylation and the logistical complexity of continuous infusion — two alternatives for extending short peptide half-lives. The original Phase I/II clinical trial by Ionescu & Frohman (2006) confirmed the mechanism and demonstrated that a single dose of CJC-1295-DAC produced measurable GH elevation persisting for 6 days, with mean IGF-1 increases of 30–70% sustained over 14 days.
GH Pulsatility: The Central Research Question
Growth hormone secretion in healthy adults is intrinsically pulsatile — typically 6–12 bursts per 24 hours, with the largest pulse occurring during slow-wave sleep. This pulsatility is not merely a pharmacokinetic curiosity; it has functional significance. GH receptor signaling, hepatic IGF-1 production, and downstream anabolic processes respond differently to pulsatile versus sustained GH exposure.
This distinction is the most consequential difference between the two CJC-1295 variants from a research design perspective.
CJC-1295 with DAC and Pulsatility Disruption
By maintaining continuous GHRH receptor stimulation over days, CJC-1295-DAC progressively blunts the normal somatostatin oscillation that gates GH pulses. The result is a more tonic, non-pulsatile GH secretion pattern. While this produces sustained IGF-1 elevation — favorable for anabolic and fat mobilization research endpoints — it may also engage GH receptor downregulation mechanisms over time, as seen with continuous exogenous GH infusion in preclinical models.
The practical concern in research contexts is that chronic DAC use may blunt the GH response to subsequent GHRH stimulation — a form of receptor desensitization analogous to that seen with other sustained peptide ligands. This hypothesis has not been formally studied with DAC, but is inferred from known GHRH receptor biology.
Mod GRF 1-29 and Physiological Pulsatility Preservation
Because Mod GRF 1-29 has a biological window of 2–3 hours, each injection produces a discrete GH pulse followed by a washout period during which somatostatin tone can reestablish. This allows the hypothalamic–pituitary axis to maintain its regulatory architecture. Research protocols using Mod GRF 1-29 typically co-administer a GH secretagogue (GHRP-2, GHRP-6, Ipamorelin) to amplify each GH pulse, a combination that more closely replicates physiological GH secretion than either compound alone.
Mod GRF 1-29 is most commonly co-administered with a GHRP — typically Ipamorelin for a cleaner GH pulse, or GHRP-2 for a larger but cortisol/prolactin-elevating pulse. The synergistic mechanism is well-characterized: GHRH analogues increase GH pulse amplitude, while GHRPs increase pulse frequency and inhibit somatostatin. Combined, they produce GH secretion greater than either alone — consistent with the dual hypothalamic regulation of GH.
IGF-1 Elevation Comparison
In the Ionescu & Frohman (2006) trial, a single 2 mg dose of CJC-1295-DAC produced mean IGF-1 increases of 52% sustained over 7–14 days. Equivalent IGF-1 elevation from Mod GRF 1-29 would require multiple daily injections over several weeks, given the compound's shorter action window and lower per-dose GH stimulation.
For research protocols where sustained IGF-1 elevation is the primary endpoint (e.g., adipose tissue reduction, recovery biomarker studies), CJC-1295-DAC offers logistical advantages. For research prioritizing GH pulse dynamics, receptor sensitivity preservation, or more granular control of the GH axis, Mod GRF 1-29 with a GHRP offers a more physiologically nuanced approach.
Stability and Storage
Both compounds are provided as lyophilized powders requiring reconstitution. Mod GRF 1-29 is generally considered more stable in solution than native GHRH due to its DPP-IV–resistant modifications. CJC-1295-DAC stability in solution has been less systematically studied, but the albumin-binding moiety remains reactive in solution and should be handled to minimize pre-injection albumin contact (e.g., avoid reconstituting in plasma-containing solvents). Standard storage for both: −20°C lyophilized, 2–8°C reconstituted for up to 4 weeks.
Research Use Only — Disclaimer. This document is prepared for laboratory and research reference purposes only. Neither CJC-1295 with DAC nor CJC-1295 without DAC (Mod GRF 1-29) is FDA-approved for any indication. All information pertains to research models and available scientific literature. This content does not constitute medical advice. Researchers must comply with applicable institutional and jurisdictional regulations.
References
- Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." *J Clin Endocrinol Metab*. 2006;91(12):4792–4797.
- Sam S, Frohman LA. "Normal physiology of hypothalamic pituitary regulation." *Endocrinol Metab Clin North Am*. 2008;37(1):1–22.
- Laferrère B, et al. "Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men." *J Clin Endocrinol Metab*. 2005;90(2):611–614.
- Arvat E, et al. "Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans." *J Endocrinol Invest*. 2000;23(8):493–495.
- Alba M, et al. "Once-monthly administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse." *Am J Physiol Endocrinol Metab*. 2006;291(6):E1290–E1294.